Evidence map›Paper›PMID 26952843›Full record

ArticleLeukemia & lymphoma2016

STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)-STAT3 pathway.

Amy Belton, Lingling Xian, Tait Huso, Michael Koo, Li Z Luo, James Turkson, Brent D G Page, Patrick T Gunning, Guosheng Liu, David L Huso and 1 more

Open access · greenAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Clinical Implications of Extracellular HMGA1 in Breast Cancer.International journal of molecular sciences · 2019
    Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Amy Beltona Hematology Division, Department of Medicine , Johns Hopkins University School of Medicine , Baltimore , MD , USA ;
Lingling Xiana Hematology Division, Department of Medicine , Johns Hopkins University School of Medicine , Baltimore , MD , USA ;
Tait Husoa Hematology Division, Department of Medicine , Johns Hopkins University School of Medicine , Baltimore , MD , USA ;
Michael Kooa Hematology Division, Department of Medicine , Johns Hopkins University School of Medicine , Baltimore , MD , USA ;
Li Z Luoa Hematology Division, Department of Medicine , Johns Hopkins University School of Medicine , Baltimore , MD , USA ;
James Turksonb Cell and Molecular Biology Department , John A. Burns School of Medicine, University of Hawaii , Honolulu , HI , USA ;
Brent D G Pagec Department of Chemistry , University of Toronto , Ontario , Canada ;
Patrick T Gunningc Department of Chemistry , University of Toronto , Ontario , Canada ;
Guosheng Liud Department of Molecular and Comparative Pathobiology , Johns Hopkins University School of Medicine , Baltimore , MD , USA ;
David L Husod Department of Molecular and Comparative Pathobiology , Johns Hopkins University School of Medicine , Baltimore , MD , USA ;
Linda M S Resara Hematology Division, Department of Medicine , Johns Hopkins University School of Medicine , Baltimore , MD , USA ;
Johns Hopkins Medicine · USJohns Hopkins University · USUniversity of Toronto · CAUniversity of Hawaiʻi at Mānoa · US

Funding

Mechanisms of Neoplastic Transformation by HMG-I/YR01CA092339 · NCI · JOHNS HOPKINS UNIVERSITY · PI RESAR, LINDA M S · 2003 to 2006
$1.2M
HMGA1 in Tumor Progression in Breast CancerR21CA149550 · NCI · JOHNS HOPKINS UNIVERSITY · PI RESAR, LINDA M S · 2010 to 2011
$387k
Developing a Screen for Novel Therapies with Reprogrammed Pancreatic Cancer CellsR03CA191621 · NCI · JOHNS HOPKINS UNIVERSITY · PI RESAR, LINDA M S · 2015 to 2016
$162k
Developing Nanotechnology to Target HMGA1 in Pancreatic CancerR03CA182679 · NCI · JOHNS HOPKINS UNIVERSITY · PI RESAR, LINDA M S · 2014 to 2015
$151k
NCI NIH HHS R01 CA092339NCI NIH HHS R03 CA182679NCI NIH HHS R03 CA191621NCI NIH HHS R21 CA149550
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Aminosalicylic AcidsAnimalsAntineoplastic AgentsCell LineageGene Expression Regulation, LeukemicHMGA1a ProteinHumansJurkat CellsMiceMice, NudePrecursor Cell Lymphoblastic Leukemia-LymphomaPrecursor Cells, B-LymphoidSignal TransductionSTAT3 Transcription FactorSulfonamidesTumor Cells, CulturedAminosalicylic AcidsAntineoplastic AgentsBP-1-102HMGA1a ProteinSTAT3 Transcription FactorSulfonamides

Identifiers

PMID26952843
PMCPMC5580963
OpenAlexW2296287591

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.